FinancialVu

Market News and Views

You are here: Home / Top Stories / : Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering

: Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering

by

Biogen’s all-cash deal is a rare-disease play.